pufa 20:4 n-6

PUFA 20:4 n‑6 refers to arachidonic acid, a 20‑carbon long‑chain polyunsaturated fatty acid with four cis double bonds in the omega‑6 position. Chemically, it is designated C20:4n‑6 and is a member of the omega‑6 family of polyunsaturated fatty acids (PUFAs). It occurs predominantly in the phospholipids of mammalian cell membranes, where it contributes to membrane fluidity and serves as a reservoir for biologically active molecules. In cellular biochemistry, ARA is integral to the structure of phosphatidylethanolamine and phosphatidylcholine, and it represents a significant proportion of the fatty acid composition in tissues such as brain, liver, and skeletal muscle. Unlike the shorter omega‑6 precursor linoleic acid, which is abundant in plant oils, arachidonic acid is found primarily in animal‑derived foods and cannot be synthesized de novo by humans; instead, it must be obtained either directly from the diet or indirectly through the elongation and desaturation of linoleic acid. Arachidonic acid has six double bonds counted from the methyl end, making it highly unsaturated and biologically reactive. Because of this unsaturation, ARA influences membrane dynamics and the function of membrane‑bound proteins. Historically, researchers identified arachidonic acid due to its abundance in brain tissue and later recognized its role as the precursor for eicosanoids, a diverse class of signaling lipids. These derivatives include prostaglandins, thromboxanes, leukotrienes, and lipoxins that mediate inflammation and homeostatic processes. Thus, arachidonic acid bridges nutritional intake and biochemical signaling, serving structural and dynamic roles within cellular physiology. Arachidonic acid is distinct from omega‑3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) by its position in the omega‑6 series. While both families are essential for human health, they often have differing and sometimes opposing roles in inflammation and metabolic regulation. ARA’s presence in phospholipid membranes and subsequent release by phospholipase enzymes underlies its importance as a signaling precursor. The body regulates ARA availability tightly because excessive free ARA is associated with pro‑inflammatory responses, whereas adequate levels are necessary for normal immune function, neuronal growth, and cell turnover. Thus, pufa 20:4 n‑6 is both a foundational structural component and a dynamic biochemical precursor in human physiology.

Arachidonic acid (ARA, PUFA 20:4n‑6) serves multiple critical functions in the human body, both as a structural fatty acid and as a biochemical precursor. One of its primary roles is as a structural component of cell membranes, especially in tissues with high metabolic and signaling activity such as the brain, muscles, and immune cells. In this role, ARA contributes to membrane fluidity, which affects receptor function and cellular transport processes. Because it is highly unsaturated, its presence influences the biophysical properties of lipid bilayers. ARA is also a precursor for eicosanoids, a broad set of locally acting signaling molecules that include prostaglandins, thromboxanes, leukotrienes, and lipoxins. These eicosanoids play central roles in regulating inflammation, platelet aggregation, vascular tone, and immune responses. The metabolism of ARA begins when it is released from membrane phospholipids by enzymes such as phospholipase A2. Once freed, ARA can be oxygenated by cyclooxygenases and lipoxygenases to form prostaglandins and leukotrienes. These metabolites orchestrate acute inflammatory responses essential for host defense and tissue healing. Importantly, some ARA metabolites are also involved in the resolution phase of inflammation, underscoring a nuanced role beyond simply promoting inflammation. Emerging research suggests that appropriate intake of ARA may influence cognitive attention and memory by modulating neuronal signaling and synaptic function, although the evidence base remains limited and requires further large trials. Although omega‑6 PUFAs have been historically viewed with caution due to their potential link with pro‑inflammatory derivatives, contemporary reviews indicate that overall intake of omega‑6 fatty acids, including ARA, as part of dietary patterns high in polyunsaturated fats is associated with favorable cardiovascular outcomes when they replace saturated fats. Observational data show that higher dietary PUFA intake is correlated with reductions in low‑density lipoprotein (LDL) cholesterol and does not significantly increase risk factors for heart disease. Controlled supplementation studies up to ~1,000–1,500 mg/day of ARA have not demonstrated adverse effects on blood lipids, platelet functions, or inflammatory parameters in healthy adults, though data remain sparse. Furthermore, ARA is essential in early development; human breast milk contains both ARA and DHA, and formulas supplemented with these fatty acids support immune development and growth similar to breastfeeding. In addition to its roles in inflammation and cardiovascular health, ARA is implicated in muscle growth and repair through signaling pathways that influence protein synthesis. In skeletal muscle, ARA influences gene expression related to muscle metabolism and may interact with omega‑3 fatty acids in optimizing tissue function. Despite its functional importance, the body can convert linoleic acid, a more prevalent dietary omega‑6 fatty acid, into ARA, meeting physiologic needs in most adults. This conversion underscores why a specific dietary reference intake for ARA has not been established. Nonetheless, maintaining balanced omega‑6 and omega‑3 intakes in the diet supports optimal cell membrane composition and metabolic health.

Unlike essential vitamins and minerals that have defined Recommended Dietary Allowances (RDAs), arachidonic acid (PUFA 20:4n‑6) does not have a specific RDA set by authoritative bodies such as the National Institutes of Health (NIH) Office of Dietary Supplements or the Institute of Medicine. Instead, dietary guidelines emphasize intake of broader categories such as total polyunsaturated fatty acids (PUFAs) and require that linoleic acid, the metabolic precursor to ARA, be consumed in adequate amounts. Linoleic acid has an Adequate Intake (AI) defined within dietary reference frameworks, but there is no separate AI or RDA exclusively for ARA. This reflects the fact that humans can endogenously synthesize arachidonic acid from linoleic acid through desaturation and elongation pathways in the body, provided that linoleic acid intake is sufficient. In practice, typical Western dietary intakes of arachidonic acid range between approximately 50 and 300 mg per day among adults consuming omnivorous diets. Foods such as meat, poultry, fish, and eggs contribute to ARA intake, with organ meats and some fish species providing higher concentrations. Because dietary arachidonic acid intake can vary widely depending on food choices, and because the body can synthesize it from linoleic acid, it is challenging to specify a universal daily requirement. For practical purposes, ensuring adequate consumption of total omega‑6 PUFAs through a balanced diet rich in nuts, seeds, and vegetable oils can support endogenous ARA synthesis, whereas direct dietary ARA contributes to tissue levels without a specific target. Factors affecting individual arachidonic acid needs include age, metabolic demands, inflammation status, and dietary patterns. Infants and young children have unique needs for long‑chain polyunsaturated fatty acids, including both ARA and docosahexaenoic acid (DHA), for brain development; human breast milk naturally supplies both fatty acids. In adult populations, conversion from linoleic acid is typically sufficient to maintain physiological ARA levels, and supplemental ARA is rarely necessary. However, specific clinical scenarios such as preterm infant nutrition or certain metabolic disorders may necessitate focused attention to ARA provision. Regardless, broad dietary frameworks recommend absorbing sufficient essential fatty acids while maintaining an overall healthy diet to support metabolic and inflammatory balance.

Deficiency of arachidonic acid (PUFA 20:4n‑6) per se is uncommon in typical Western diets, as most individuals obtain sufficient linoleic acid—the precursor to ARA—from plant oils, nuts, and seeds. The human body can convert linoleic acid to arachidonic acid through desaturation and elongation pathways, and this endogenous synthesis generally prevents outright deficiency. Nonetheless, in specific contexts such as severe essential fatty acid deficiency or strict plant‑based diets very low in linoleic acid, signs of insufficient arachidonic acid or overall omega‑6 PUFA status may manifest. Clinical indicators of essential fatty acid deficiency can include dry, scaly skin (dermatitis), brittle hair, hair loss, and impaired wound healing. Because PUFAs are integral to skin barrier function and cell membrane integrity, compromised levels may disrupt normal skin physiology. Additionally, cognitive and mood changes, poor growth in children, and altered immune responses may accompany broader essential fatty acid insufficiency. ARA plays a role in immune cell signaling and inflammatory responses; thus, inadequate status may theoretically affect immune competence and tissue repair processes. Laboratory testing for fatty acid profiles in plasma or erythrocyte membranes can help assess essential fatty acid status and may show low proportions of long‑chain omega‑6 fatty acids including arachidonic acid when deficiency is present. Populations at increased risk for compromised PUFA status include individuals with malabsorption syndromes, severe dietary restrictions, or genetic disorders affecting fatty acid metabolism. Patients with conditions such as cystic fibrosis, cholestatic liver disease, or pancreatic insufficiency may exhibit essential fatty acid deficiencies due to impaired absorption of dietary fats. In infants and young children, especially those born prematurely, insufficient provision of both arachidonic acid and docosahexaenoic acid (DHA) can affect neural development and growth. Human breast milk naturally contains both ARA and DHA, supporting early development; formula supplementation aims to mimic these levels. Routine assessment of arachidonic acid levels is not common in clinical practice for healthy adults because deficiency is rare and can usually be inferred from linoleic acid status and overall dietary fat intake. When testing is performed, optimal ranges are determined by fatty acid profiling laboratories and may vary; clinicians interpret results in context with clinical signs and broader dietary intake.

Because arachidonic acid is found primarily in animal‑derived foods, the richest dietary sources are meats, organ meats, eggs, and certain fish. Unlike shorter omega‑6 fatty acids such as linoleic acid, which are abundant in vegetable oils, ARA is virtually absent from plant foods and must be consumed directly from animal tissues or synthesized endogenously from linoleic acid. According to nutrient ranking tools based on USDA FoodData Central and legacy data, the highest concentrations of arachidonic acid per 100 grams are found in certain fish like raw Coho salmon, variety meats such as kidney and liver, and organ meats from beef and lamb. These foods provide hundreds of milligrams of ARA per serving, substantially higher than lean muscle meats. Egg yolk is another important source; dried yolk contains over a gram of ARA per 100 grams, while cooked or raw yolk provides several hundred milligrams. Whole eggs also contribute to dietary ARA intake, though at lower levels than pure yolk. The presence of arachidonic acid in these foods reflects its role in cell membranes; organ meats and fish tissues have higher membrane lipid content relative to lean muscle. Consuming a variety of animal foods can help individuals achieve a range of ARA intakes. For example, a 3 ounce (85 gram) serving of cooked beef kidney may provide over 300 mg of arachidonic acid, while the same portion of salmon can offer up to approximately 200–700 mg depending on species and preparation. Eggs, particularly yolks, provide significant amounts when consumed in multiple servings. Compared with these high‑ARA foods, typical servings of lean meats such as chicken breast or lean pork contain lower but still meaningful amounts that contribute cumulatively to daily intake. For individuals following plant‑based diets, endogenous synthesis from linoleic acid becomes the primary source of arachidonic acid. Linoleic acid is abundant in plant oils such as safflower, corn, and soybean oils, and these PUFAs support the body’s capability to produce ARA when intake is sufficient. However, direct dietary sources remain the most efficient way to obtain arachidonic acid without relying solely on metabolic conversion.

Arachidonic acid absorption occurs in the small intestine alongside other dietary fats. Because ARA is a long‑chain polyunsaturated fatty acid, it is incorporated into mixed micelles formed with bile salts prior to uptake by enterocytes. Inside intestinal cells, arachidonic acid is re‑esterified into triglycerides and phospholipids and incorporated into chylomicrons for transport via the lymphatic system to circulation. The bioavailability of arachidonic acid depends on fat content of the meal; concurrent intake of dietary fat enhances micelle formation and facilitates absorption of ARA and other fatty acids. Factors that inhibit fat absorption—such as reduced bile acid secretion, pancreatic insufficiency, or medications that bind bile acids—can reduce arachidonic acid absorption. Individuals with conditions like cholestatic liver disease, cystic fibrosis, or inflammatory bowel diseases may have compromised absorption of long‑chain fatty acids, including ARA, due to impaired lipid digestion. Additionally, very low‑fat diets may limit arachidonic acid uptake because insufficient fat reduces bile release and micelle formation. Pairing arachidonic acid–rich foods with dietary fat improves absorption efficiency. This is why high‑fat meals typically provide more efficient uptake of long‑chain PUFAs compared to low‑fat meals. ARA integration into cell membranes depends on its relative abundance compared with other fatty acids; diets high in omega‑3 PUFAs can competitively influence incorporation into phospholipids, reflecting interplay between these fatty acid families in membrane composition. Timing of intake relative to other macronutrients has minimal impact if dietary fat is adequate, though extremely low‑fat meals may marginally reduce absorption efficiency.

Most healthy adults do not require arachidonic acid supplements because endogenous synthesis from linoleic acid and dietary intake from common foods typically meet physiological needs. Supplementation with arachidonic acid has been studied in specific contexts, such as infant nutrition and muscle physiology, but large‑scale evidence supporting routine supplementation in adults is limited. Controlled studies have administered up to approximately 1,000–1,500 mg/day of arachidonic acid without observing significant adverse effects on blood lipids, platelet activity, or inflammation markers in healthy adults, though more research is needed to define safety and efficacy comprehensively. Infant formulas often include arachidonic acid alongside DHA to mimic human breast milk, which naturally contains both long‑chain PUFAs and supports neural and immune development. In adults, claims about performance enhancement or cognitive benefits from supplemental ARA are not robustly supported by large meta‑analyses; some small trials suggest potential effects on attention, mood, or coronary circulation, but evidence quality is variable. Populations with restrictive diets, such as vegans or individuals with malabsorption syndromes, may consider monitoring essential fatty acid status and discussing with clinicians whether specific supplementation strategies are warranted. When supplements are used, they should be sourced from reputable manufacturers to ensure purity and accurate dosing. Arachidonic acid supplements are typically provided in triglyceride or ethyl ester forms; triglyceride forms may offer better incorporation into body lipid pools. Users should be cautious of high doses and consider balancing omega‑6 and omega‑3 intakes to support metabolic homeostasis. Because arachidonic acid can influence inflammatory pathways, individuals with chronic inflammatory conditions should consult healthcare professionals before initiating supplementation.

No official tolerable upper intake level (UL) exists for arachidonic acid because most populations do not achieve levels associated with toxicity through diet alone. Typical dietary intakes are estimated between approximately 50–300 mg/day in Western diets, with eggs, meat, fish, and organ meats contributing the majority of intake. Some controlled supplementation studies have administered up to and beyond 1,000 mg/day without overt adverse outcomes in healthy adults, though earlier research has reported exaggerated platelet aggregation at very high doses (e.g., 6 g/day) that prompted early study termination. This suggests that extreme arachidonic acid intake may carry thrombotic risk, but such doses far exceed usual dietary exposures. Symptoms of excessive arachidonic acid exposure are not well defined in humans, partly because high‑dose research is limited. Hypothetically, overly high ARA availability could shift eicosanoid production toward pro‑inflammatory mediators, potentially exacerbating existing inflammatory conditions. However, contemporary analyses indicate that increased omega‑6 PUFA diets do not necessarily increase inflammation biomarkers when they displace saturated fats in the diet. Nonetheless, prolonged intake of very high ARA levels without balancing omega‑3 fatty acids may skew membrane fatty acid composition and inflammatory mediator profiles. Individuals with predispositions to thrombosis, cardiovascular disease, or chronic inflammation should approach supplemental arsenic with caution and consult clinicians. Because ARA participates in platelet aggregation pathways, interactions with anticoagulant medications could theoretically influence clotting dynamics, though evidence is limited. Overall, within normal dietary ranges, arachidonic acid intake from food is not associated with toxicity, but supplementation at high doses should be approached cautiously and under professional supervision.

Arachidonic acid interacts indirectly with medications that influence eicosanoid pathways. Nonsteroidal anti‑inflammatory drugs (NSAIDs) such as aspirin and ibuprofen inhibit cyclooxygenase enzymes responsible for converting arachidonic acid into prostaglandins and thromboxanes, altering inflammatory responses and platelet function. Because these drugs block enzyme pathways downstream of ARA release, they can modify the balance of eicosanoid production, impacting inflammation and clotting. Corticosteroids reduce phospholipase A2 activity, limiting arachidonic acid release from membrane phospholipids and thereby decreasing downstream mediator synthesis. Such interactions underpin the mechanisms of many anti‑inflammatory medications. Anticoagulant drugs, such as warfarin and direct oral anticoagulants (DOACs), interact with pathways related to platelet function influenced by arachidonic acid metabolites. Although dietary ARA does not directly affect warfarin metabolism, changes in eicosanoid‑mediated platelet activity could theoretically influence bleeding risk in susceptible individuals. Patients on anticoagulant therapy should discuss dietary fatty acid changes with healthcare providers to ensure stable therapeutic effects. Similarly, medications targeting leukotriene pathways, such as montelukast, align with the arachidonic acid cascade, potentially modulating inflammatory responses in asthma and allergic conditions. Other nutrients can affect arachidonic acid metabolism. Supplementation with omega‑3 fatty acids (EPA and DHA) competes with arachidonic acid for incorporation into membranes and for enzymes involved in eicosanoid synthesis, often leading to reduced production of pro‑inflammatory ARA‑derived mediators. High doses of omega‑3 supplements may shift the balance of eicosanoids, which is sometimes therapeutically desirable but should be considered when interpreting inflammatory markers. Overall, arachidonic acid’s interactions with medications and nutrients occur within the broader context of lipid mediator networks, and clinical decisions should consider whole‑diet patterns and individual health status.

Common Forms: Triglyceride capsules, Ethyl ester formulations

Typical Doses: ~500–1500 mg/day in studies

When to Take: With meals containing fat

Best Form: Triglyceride form

⚠️ Interactions: NSAIDs (cyclooxygenase inhibitors), Corticosteroids, Anticoagulants, High‑dose omega‑3 supplements